Abstract
The YAP transcription coactivator has been implicated as an oncogene and is amplified in human cancers. Previously, it has been shown that CCN2 (connective tissue growth factor, CTGF) is a target of the tumor promoting YAP and its transcription factor target TEAD. A recent report in Genes and Development by Zhao and colleagues (Genes Dev 22:1962–1971 2008) has extended these initial observations to show that CCN2 plays an important role in the growth-promoting function of YAP. These data confirm the role of CCN2 as a key oncogenic mediator. This report briefly summarizes these findings.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Babic AM, Kireeva ML, Kolesnikova TV, Lau LF (1998) CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 95:6355–6360, doi:10.1073/pnas.95.11.6355
Blom IE, Goldschmeding R, Leask A (2002) Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol 21:473–482, doi:10.1016/S0945-053X(02)00055-0
Deng YZ, Chen PP, Wang Y, Yin D, Koeffler HP, Li B et al (2007) Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta catenin-T-cell factor/Lef signaling. J Biol Chem 282:36571–36581, doi:10.1074/jbc.M704141200
Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel RE (2004) Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer 11:781–791, doi:10.1677/erc.1.00825
Leask A, Holmes A, Black CM, Abraham DJ (2003) Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem 278:13008–13015, doi:10.1074/jbc.M210366200
Libermann TA, Zerbini LF (2006) Targeting transcription factors for cancer gene therapy. Curr Gene Ther 6:17–33, doi:10.2174/156652306775515501
Oikawa T (2004) ETS transcription factors: possible targets for cancer therapy. Cancer Sci 95:626–633, doi:10.1111/j.1349-7006.2004.tb03320.x
Pickles M, Leask A (2007) Analysis of CCN2 promoter activity in PANC-1 cells: regulation by ras/MEK/ERK. J Cell Commun Signal 1:85–90, doi:10.1007/s12079-007-0008-9
Rachfal AW, Luquette MH, Brigstock DR (2004) Expression of connective tissue growth factor (CCN2) in desmoplastic small round cell tumour. J Clin Pathol 57:422–425, doi:10.1136/jcp.2003.012344
Shimo T, Kubota S, Yoshioka N, Ibaragi S, Isowa S, Eguchi T et al (2006) Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res 21:1045–1059, doi:10.1359/jbmr.060416
van Beek JP, Kennedy L, Rockel JS, Bernier SM, Leask A (2006) The induction of CCN2 by TGf beta1 involves Ets-1. Arthritis Res Ther 8:R36
Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML (2001) TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev 15:1229–1241, doi:10.1101/gad.888601
Xie D, Yin D, Wang HJ, Liu GT, Elashoff R, Black K et al (2004) Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 10:2072–2081, doi:10.1158/1078-0432.CCR-0659-03
Zhao B, Ye X, Yu J, Li L, Li W, Li S et al (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22:1962–1971, doi:10.1101/gad.1664408